Apply for an NP/PA Waiver

Waiver-Course-Horizontal-Transparent

About the Waiver

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law as Public Law 114-198. One of CARA’s important provisions expands access to substance use treatment services and overdose reversal medications—including the full spectrum of services from prevention to medication-assisted treatment (MAT) and recovery support—by extending the privilege of prescribing buprenorphine in office-based settings to qualifying nurse practitioners (NPs) and physician assistants (PAs) until Oct. 1, 2021.

In order to prescribe, NPs and PAs must fill out a Notification of Intent form.

How to Apply

There are two ways to apply:

  • Apply online by clicking here. Applications are sent directly to the Center for Substance Abuse Treatment (CSAT).
  • Apply via your smartphone using SAMHSA's mobile app MATx. Click here to learn more about MATx.


Completing the Notification of Intent Form

NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Notification of Intent form.

NPs and PAs must send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

To be redirected to SAMHSA's website, click here.